1076220-92-2

Upstream product

• 1076220-91-1 ethyl 2-{7-bromo-1-[2-(tert-butylamino)-2-oxoethyl]-2-[4-(trifluoromethoxy)phenyl]-1H-indol-5-yl}-2-methylpropanoate 
• 1076220-90-0 ethyl 2-{7-bromo-2-[4-(trifluoromethoxy)phenyl]-1H-indol-5-yl}-2-methylpropanoate 
• 1076220-89-7 ethyl 2-(4-amino-3-bromo-5-{[4-(trifluoromethoxy)phenyl]ethynyl}phenyl)-2-methylpropanoate 
• 239104-48-4 trimethyl-[2-[4-(trifluoromethoxy)phenyl]ethynyl]silane 
• 1076220-88-6 ethyl 2-(4-amino-3-bromo-5-iodophenyl)-2-methylpropanoate 
• 357193-01-2 ethyl 2-(4-amino-3-iodophenyl)-2-methylpropanoate 
• 160542-02-9 1-ethynyl-4-(trifluoromethoxy)benzene 
• 103962-05-6 1-iodo-4-(trifluoromethoxy)benzene 

Downstream Products

• 1076219-30-1 2-{7-bromo-1-[2-(tert-butylamino)-2-oxoethyl]-2-[4-(trifluoromethoxy)phenyl]-1H-indol-5-yl}-N-(tert-butyl)-2-methylpropionamide 

Relevant academic research and scientific papers

2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

2-Substituted indole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.